AstraZeneca announces that a phase III trial evaluating Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) has been inconclusive.

Indeed, the trial failed to meet its primary objective of improving overall survival compared with paclitaxel plus placebo, either in the overall population or in a subgroup of patients with specific biomarker alterations (PIK3CA, AKT1 or PTEN).

TNBC is difficult to treat due to the lack of known actionable biomarker targets, and chemotherapy remains the mainstay of treatment.

Despite the disappointing results, these data are important for a better understanding of this aggressive form of breast cancer, stresses the laboratory, which is continuing its research on Truqap and other treatments as part of its clinical development program.



Copyright (c) 2024 CercleFinance.com. All rights reserved.